home / stock / trgnf / trgnf short
Short Information | Transgene S.A. (OTCMKTS:TRGNF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 12,099 |
Total Actual Volume | 15,315 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 17 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 605 |
Average Short Percentage | 82.39% |
Is there a TRGNF Short Squeeze or Breakout about to happen?
See the TRGNF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
06-20-2023 | $2 | $2.1 | $2.1 | $2 | 2,200 | 200 | 9.09% |
06-05-2023 | $2.04 | $2 | $2.04 | $2 | 300 | 100 | 33.33% |
08-08-2022 | $2.2 | $2.2 | $2.2 | $2.2 | 475 | 475 | 100% |
07-11-2022 | $2.45 | $2.45 | $2.45 | $2.45 | 700 | 700 | 100% |
07-07-2022 | $2.45 | $2.4499 | $2.45 | $2.4499 | 750 | 500 | 66.67% |
07-06-2022 | $2.45 | $2.45 | $2.45 | $2.45 | 100 | 100 | 100% |
07-05-2022 | $2.5 | $2.35 | $2.5 | $2.35 | 350 | 350 | 100% |
06-01-2022 | $2.8 | $2.8 | $2.8 | $2.8 | 100 | 100 | 100% |
04-01-2022 | $2.83 | $2.83 | $2.83 | $2.83 | 123 | 123 | 100% |
03-30-2022 | $2.82 | $2.83 | $2.83 | $2.82 | 2,205 | 2,000 | 90.7% |
03-01-2022 | $2.3 | $2.3 | $2.3 | $2.3 | 2,000 | 2,000 | 100% |
02-09-2022 | $2.82 | $2.82 | $2.82 | $2.82 | 1,922 | 1,872 | 97.4% |
12-07-2021 | $2.976 | $2.976 | $2.976 | $2.976 | 300 | 300 | 100% |
11-23-2021 | $3.05 | $3.062 | $3.062 | $3.05 | 400 | 400 | 100% |
10-13-2021 | $2.79 | $2.776 | $2.79 | $2.776 | 600 | 500 | 83.33% |
07-27-2021 | $2.74 | $2.54 | $2.74 | $2.54 | 260 | 149 | 57.31% |
06-02-2021 | $3.7 | $3.665 | $3.7 | $3.665 | 1,080 | 1,080 | 100% |
05-10-2021 | $3.4 | $3.316 | $3.4 | $3.316 | 290 | 190 | 65.52% |
03-08-2021 | $3.22 | $3.22 | $3.22 | $3.22 | 800 | 800 | 100% |
01-22-2021 | $3.09 | $2.995 | $3.09 | $2.995 | 360 | 160 | 44.44% |
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...